持續性角膜上皮缺損（PCED）：全球市場展望、流行病學、競爭格局與市場預測報告（32個主要市場），2025-2035年

市場概覽

• 德國持續性角膜上皮缺損市場預計將從2025年的2,384萬美元成長到2035年的2.1,289億美元，顯示市場擴張強勁。
• 以下因素推動市場成長：
• 難治性和復發性病例的診斷數量增加
• 擴大先進生物製藥和再生醫學在眼科治療的應用。
• 改善獲得專業眼科護理和罕見疾病管理的機會
• 市場規模得益於創新治療方法的高價定價，以及對能夠促進角膜癒合和預防復發的治療方法日益成長的需求。
• 針對角膜再生、神經癒合和上皮修復的新治療方法有望在德國創造巨大的商業性機會。
• 未來的成長取決於先進生物製藥和治療方法的成功引進，這些製劑和治療方法可以降低復發率，同時改善長期視力預後。

持續性角膜上皮缺損（PCED）概述

持續性角膜上皮缺損（PCED）是嚴重的眼科疾病可能導致角膜基質溶解、穿孔和永久性瘢痕形成。診斷方法包括裂隙燈顯微鏡檢查（螢光素染色）、角膜感覺追蹤和前節OCT檢查。基礎治療方法包括使用不含防腐劑的潤滑劑、治療性繃帶式隱形眼鏡以及口服小劑量多西環素以抑制組織分解性基質金屬蛋白酶。生物修復方法包括自體或異體血清眼藥水，但重組神經生長因子塞尼格明是目前核准的第一線標準治療方法，特別適用於神經營養性缺損。到2026年，目標是透過非神經營養途徑，利用Lufepilsen滴眼液和Secretome滴眼液等研發治療方法，實現機械和細胞修復。羊膜移植和眼瞼縫合術將僅限於需要積極治療的難治性病例。

主要亮點

• 在德國，復發性和難治性持續性角膜上皮缺損（PCED）病例數預計將從2025年的718 例增加到2035年的827 例，反映出該疾病負擔的逐漸增加。
• 持續性角膜上皮缺損是一種嚴重的眼表疾病，與角膜癒合受損、視力喪失風險以及疾病復發進展有關。
• 人們意識的提高、眼科診斷技術的進步以及神經營養性角膜炎和糖尿病等潛在疾病盛行率的上升，都促進了診斷率的提高。
• 對於復發或難治性疾病患者而言，傳統潤滑劑、繃帶式隱形眼鏡和輔助療法均無法充分滿足其治療需求，因此仍存在著巨大的未滿足需求。
• 隨著人們對生物製藥、再生醫學和新型眼科製劑的關注度不斷提高，預計在預測期內，治療格局將發生巨大變化。
• 受生物製藥普及和人們對罕見角膜疾病的認知不斷提高的推動，預計到2030年，全球神經營養性角膜炎治療市場將以約 9%的年複合成長率成長。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

主要企業

• Dompe Farmaceutici SpA
• Glaukos Corporation

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要治療方法 - 概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章 未滿足的需求與TPP分析

• 主要未滿足需求及新興療法的未來成就前景
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Global Persistent Corneal Epithelial Defect (PCED) Market Outlook

Thelansis's "Global Persistent Corneal Epithelial Defect (PCED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Persistent Corneal Epithelial Defect treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Persistent Corneal Epithelial Defect (PCED) Overview

Persistent corneal epithelial defect (PCED) is a severe ocular pathology defined by the failure of the corneal epithelium to close within two weeks despite standard management. Resulting from a disrupted regenerative cycle, it stems from neurotrophic keratopathy, limbal stem cell deficiency, chemical burns, or severe ocular surface disease. Left untreated, chronic defects risk stromal melting, perforation, and permanent scarring. Diagnosis relies on slit-lamp biomicroscopy with fluorescein staining, corneal sensitivity tracking, and anterior segment OCT. Foundational management utilizes preservative-free lubrication, therapeutic bandage contact lenses, and low-dose oral doxycycline to inhibit tissue-degrading matrix metalloproteinases. Biologic repair utilizes autologous or allogeneic serum drops, while the recombinant nerve growth factor cenegermin serves as the approved frontline standard specifically for neurotrophic defects. In 2026, non-neurotrophic pathways target mechanical and cellular restoration via pipeline options like lufepirsen ophthalmic gel or secretome drops. Amniotic membrane transplantation or tarsorrhaphy is reserved for refractory cases requiring aggressive closure.

Key Highlights

• In Germany, relapse and refractory Persistent Corneal Epithelial Defect (PCED) cases are projected to increase from 718 patients in 2025 to 827 patients by 2035, reflecting a gradual rise in disease burden.
• Persistent Corneal Epithelial Defect remains a serious ocular surface condition associated with impaired corneal healing, vision loss risk, and recurrent disease progression.
• Increasing awareness, improved ophthalmic diagnostics, and rising prevalence of underlying conditions such as neurotrophic keratitis and diabetes are contributing to higher diagnosis rates.
• Significant unmet need persists in relapse and refractory patients who demonstrate inadequate response to conventional lubricants, bandage contact lenses, and supportive therapies.
• Growing focus on biologics, regenerative therapies, and novel ophthalmic formulations is expected to transform the treatment landscape over the forecast period.
• The global neurotrophic keratitis treatment market is projected to grow at nearly 9% CAGR through 2030, supported by increasing biologic adoption and expanding recognition of rare corneal disorders.

Market Overview

• The Germany Persistent Corneal Epithelial Defect market is projected to grow from USD 23.84 million in 2025 to USD 212.89 million by 2035, indicating strong market expansion.
• Market growth is driven by:
• Increasing diagnosis of refractory and relapse cases
• Rising adoption of advanced biologics and regenerative ophthalmic therapies
• Improved access to specialty eye care and rare disease management
• Market value is supported by premium pricing of innovative therapies and growing demand for treatments capable of accelerating corneal healing and preventing recurrence.
• Emerging therapies targeting corneal regeneration, nerve healing, and epithelial repair are expected to create substantial commercial opportunities in Germany.
• Future growth will depend on the successful adoption of advanced biologics and therapies capable of improving long-term visual outcomes while reducing recurrence rates.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Dompe Farmaceutici S.p.A.
• Glaukos Corporation

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)